Seagen's breast cancer therapy meets main goal in late-stage study (updated)
16/08/2023 13:30
(Adds details on the therapy and background throughout)
Aug 16 (Reuters) - Seagen SGEN.O said on Wednesday its
breast cancer therapy in combination with Roche's ROG.S
Kadcyla helped extend the time patients lived without their
disease progressing in a late-stage trial.
Pfizer Inc PFE.N has agreed to acquire Seagen in a
$43 billion
deal to gain access to its targeted cancer therapies.
The therapy, Tukysa, chemically known as tucatinib, is
approved in the United States to be used in combination with
Roche’s Herceptin and Xeloda in patients whose cancer has
worsened or spread despite at least one prior round of
treatment.
Kadcyla belongs to a class of drugs antibody-drug
conjugates (ADCs), which have been described as "guided-missile"
cancer drugs.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju
Samuel)
((Mariam.ESunny@thomsonreuters.com;))